Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on vitamin B3 and NAD+ precursor supplements including NMN, NR, and niacin. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you take statins, blood pressure medications, or anticoagulants, or if you have a history of liver disease, diabetes, or gout.

The question behind the supplement shelf

Japan’s pharmaceutical companies produce more NMN than almost any other country — Mitsubishi Gas Chemical and Shinkoso are among the largest global suppliers. That industrial fact makes Japan a useful vantage point for asking a question that frequently gets buried in the premium supplement conversation: if NMN and NR are marketed as novel NAD+ boosters, how do they actually compare with niacin, a vitamin B3 form that has been studied since the 1950s?

The answer depends on which axis you care about — regulatory clarity, evidence depth on clinical endpoints, cost, or side effects. Those four axes do not point toward the same answer.

Three molecules, one metabolic target

All three compounds are forms of vitamin B3. All three serve as NAD+ precursors. The distinction is pathway, structure, and history.

Nicotinic acid and nicotinamide (niacin) are the foundational forms. Nicotinic acid (the form that causes skin flushing) and nicotinamide, also called niacinamide (the no-flush form), both convert to NAD+ through the Preiss-Handler pathway and the salvage pathway respectively. They have been studied at supplemental and pharmacological doses for decades.

NR (nicotinamide riboside) is a nucleoside form of vitamin B3 characterized as an NAD+ precursor in the early 2000s. ChromaDex developed the NIAGEN branded form and has sponsored most of the published human trials. It holds an accepted New Dietary Ingredient (NDI) notification from the US FDA — a clear regulatory baseline as a dietary supplement in the US market.

NMN (nicotinamide mononucleotide) is a further step along the same biosynthetic pathway: NR plus a phosphate group. Japan’s pharmaceutical-scale production capacity makes NMN more widely available and price-competitive there than in most Western markets. In the US, however, the FDA determined in 2022 that NMN does not qualify as a dietary supplement due to its prior investigational drug (IND) status. Commercial sales continue under legal challenge; the regulatory position remains unsettled.

The three molecules are biochemically close. Each can raise blood NAD+ levels under appropriate conditions. What they differ in is the quality of evidence supporting that outcome in humans, the populations studied, and the side-effect profile.

NAD biosynthesis operates through three distinct routes — the de novo pathway from tryptophan, the Preiss-Handler pathway from niacin, and the salvage pathway from NR/NMN — and the relative efficiency of these routes determines how well supplementation works; NAD Biosynthesis: Salvage Pathway, Kynurenine and Longevity Research covers the mechanistic background in full.

Evidence by compound

Niacin

Niacin has the longest published research history of any NAD+ precursor — but most of that history addresses pharmacological doses used for lipid modification, not NAD+ supplementation in the sense supplement marketing implies.

The AIM-HIGH trial (NEJM 2011, PubMed 21848462) added extended-release niacin at 1,500–2,000 mg/day to statin therapy in 3,414 cardiovascular disease patients. HDL increased and triglycerides fell. The primary composite cardiovascular endpoint showed no statistically significant reduction. The trial was stopped early for futility.

HPS2-THRIVE (NEJM 2014, PubMed 24552317) enrolled 25,673 patients and found that niacin plus laropiprant added to statin therapy produced no cardiovascular event benefit despite HDL improvement, while generating increased rates of adverse events — muscle symptoms, new-onset diabetes, and gastrointestinal issues among them.

What these trials established: at pharmacological doses (1.5–3 g/day) used specifically to modify lipid panels, niacin adds no cardiovascular endpoint benefit beyond statins alone and introduces meaningful adverse event risk in the populations studied. This is the trial record most often cited when people say “niacin doesn’t work.”

What these trials did not address: whether nicotinamide (the no-flush form) at supplement doses of 250–500 mg/day meaningfully raises NAD+ compared with NR or NMN at similar doses. No published head-to-head RCT has addressed this question directly. Mechanistic evidence suggests all three forms should raise NAD+ at appropriate doses, with likely differences in dose-response curves and tissue distribution. The evidence gap is not evidence of equivalence.

A Japan-specific note: dietary niacin intake is historically high in Japanese populations through seafood consumption. Tuna, bonito (katsuobushi), and salmon are concentrated dietary niacin sources. JPHC cohort data does not isolate niacin intake specifically from longevity outcomes, but Japanese dietary patterns combine multiple vitamin B3 pathways through food. This is context, not evidence that diet substitutes for supplementation at the doses studied in NAD+ trials.

NR

ChromaDex-sponsored trials have established that NR raises blood NAD+ at doses of 250–1,000 mg/day across multiple randomized controlled designs. The dose-response curve appears to flatten above roughly 500 mg/day. A 2020 trial in healthy older adults at 1,000 mg/day for 21 days confirmed NAD+ raising in whole blood, with secondary findings on mobility biomarkers that did not reach statistical significance.

The NR evidence base is modestly more voluminous than the NMN base in terms of total published trials, largely due to the ChromaDex research partnership. Most published trials use biomarker endpoints — blood NAD+ levels, insulin sensitivity markers, blood pressure — rather than hard clinical outcomes. Benefit at the level of disease endpoints has not been established in either direction.

NR’s US regulatory position remains the clearest of the three: NDI-accepted, unambiguously a legal dietary supplement. The primary branded form is Tru Niagen (ChromaDex NIAGEN), available with NSF Certification for third-party quality verification, on Amazon US.

NMN

NMN has been the subject of the most-discussed Japan-origin human trials. Yoshino et al. (2021, collaborating with Keio University) enrolled 25 postmenopausal women with prediabetes at 250 mg/day for 10 weeks and found improved muscle insulin sensitivity. Igarashi et al. (2022, Keio) found modest changes in walking speed and grip strength in older adults at 250 mg/day versus placebo. Liao et al. (2023) tested 300, 600, and 900 mg/day in 80 middle-aged adults and found dose-dependent NAD+ increases with modest subjective wellness improvements but small and inconsistent objective performance changes.

Multiple 2024–2025 Japanese and Chinese trials at 250–1,000 mg/day for 4–24 weeks broadly replicate the same pattern: NAD+ raises in blood, subjective measures tend to improve, hard-endpoint results remain modest and inconsistent across study populations.

Japan’s pharmaceutical-scale NMN production affects the cost landscape domestically. Internationally, brands with published certificates of analysis include ProHealth Longevity NMN and Renue By Science.

Side effects and clinically relevant interactions

Nicotinic acid (niacin) produces skin flushing (prostaglandin-mediated vasodilation) in most users at doses above roughly 50 mg, worsening at higher doses. At pharmacological doses, the adverse event profile observed in AIM-HIGH and HPS2-THRIVE includes new-onset diabetes risk, gastrointestinal symptoms, and liver enzyme elevation. At standard supplemental doses of 50–100 mg, tolerability is generally acceptable. The flush is not medically dangerous but is physically uncomfortable; slow dose titration reduces its severity.

Nicotinamide (niacinamide) does not cause flushing. At high doses above approximately 3 g/day, liver enzyme elevation has been reported in published case series. At the 250–500 mg supplemental range, tolerability in published data is clean.

NR shows a clean tolerability record across published trials. Occasional mild gastrointestinal discomfort, headache, and — at very high doses — mild flushing (likely from metabolic conversion pathways) are the most commonly reported adverse events, at rates broadly comparable to placebo in controlled designs.

NMN similarly shows clean short-term tolerability across published trials. Mild GI discomfort at higher doses is the most consistently reported adverse effect. Long-term safety data beyond 24 months remains preliminary for both NR and NMN.

Interactions to clarify before starting any of the three:

• Statins: Niacin at pharmacological doses has shown additive risks in the major cardiovascular trials. NMN and NR at supplement doses have not been formally evaluated for statin interaction in RCTs.
• Diabetes medications: Both NMN and NR appear in trials with insulin sensitivity endpoints; anyone on antidiabetic medications should discuss potential additive metabolic effects.
• Anticoagulants: High-dose niacin has been associated with clotting-related effects in clinical settings. NMN and NR have no published interaction data with anticoagulants.
• Gout or hyperuricemia history: High-dose niacin is associated with elevated uric acid. The relevant dose is pharmacological (grams per day); standard supplemental doses carry lower risk, but a clinician conversation is appropriate.

Where Japan fits in the larger picture

Japan’s role in this comparison goes beyond the marketing angle. The country’s pharmaceutical-scale NMN production capacity, combined with a regulatory environment that does not carry the FDA’s IND-based restriction, has enabled the clinical trial pipeline behind several of the most-cited human NMN studies. Japan also provides centenarian-dense cohort populations — approximately 92,000 centenarians as of 2023 — that give researchers study groups with unusual relevance to aging interventions.

That production and research concentration does not translate into evidence superiority. Japanese NMN trials share the same limitations as trials from other countries: small samples, short durations, biomarker rather than clinical-outcome endpoints, and population-specific findings that may not generalize. The Yoshino et al. (2021) sample of 25 women with prediabetes is a meaningful mechanistic signal, not a population-level proof-of-concept.

What Japan’s production position does provide: a more competitive domestic NMN market with established pharmaceutical-grade quality standards. Japanese-origin NMN available through established international distributors carries quality infrastructure closer to pharmaceutical manufacturing than the fragmented US supplement supply chain. That is a process quality argument, not a clinical efficacy one — and the distinction matters for how you interpret the Japan angle.

Practical buying considerations

Niacin / nicotinamide: The most cost-effective option if the goal is addressing a dietary B3 gap or general B vitamin coverage. As a deliberate NAD+ booster in the dose range where NMN and NR have been studied (250–1,000 mg/day), the absence of direct comparison trials means you cannot confidently extrapolate from the niacin pharmacology record. The cardiovascular trial results at high pharmacological doses do not argue for taking niacin for longevity reasons. Niacinamide is available at very low cost on Amazon US.

NR (Tru Niagen): Best regulatory position in the US, a consistent evidence base from ChromaDex-sponsored trials, and NSF Certification available for the primary product. Monthly cost runs approximately $40–55 at 300 mg/day. For adults who want a well-documented NAD+ precursor with established quality verification, NR remains the most straightforward option.

NMN: A growing Japanese-led trial base and pharmaceutical-grade production infrastructure at the source. US regulatory ambiguity is real and not yet resolved. Brands with published certificates of analysis — ProHealth Longevity, Renue By Science — represent the practical quality filter for international buyers. Typical dose range studied is 250–500 mg/day; doses above 500 mg/day show diminishing returns on NAD+ raising in available data.

Who should not take NAD+ precursor supplements without physician guidance

• Anyone on active cancer therapy — NAD+ metabolism intersects with pathways relevant to cell biology; the implications are not established in either direction in human trials, but the conversation with your oncologist is appropriate before starting
• Anyone with gout or hyperuricemia, given niacin’s documented uric acid association (less established for NR and NMN but not ruled out)
• Anyone on warfarin or other anticoagulant therapy
• Pregnant or breastfeeding individuals — none of the three compounds have been studied in these populations
• Anyone with liver disease — all three compounds involve hepatic metabolism
• Adolescents — all published trial populations have been adults

For adults outside those risk groups, the comparison narrows to two practical options: NR for regulatory clarity and a consistent brand-quality track record, or NMN for access to Japan-origin pharmaceutical-grade production and a growing Japan-led trial base. Niacin at supplement doses occupies a different use case — addressing dietary vitamin B3 gaps — and the pharmacological-dose cardiovascular trial record does not support it as a longevity supplement in the dose and population context where NMN and NR are currently studied.

---

See also: Best NMN Supplement Brands Compared: Dose, Third-Party Testing, and Price, NMN vs NR: What Human Trials Actually Compare on Dose, Cost, and Safety, Japan Anti-Aging Clinical Trials: What Keio, Tokyo University, and TMDU Are Actually Testing, Astragalus and Telomere Biology: Astragaloside IV, TA-65, and What the Research Shows.